에서 실시간으로 운영 중이에요! 자세히 알아보기
WGS 아이콘

GeneDx Holdings

63.61 USD
-6.61
9.41%
장 마감 시점 업데이트됨 10월 16일 PM 4:00 EDT
프리마켓
시간외 거래
64.85
+1.24
1.95%
1일
-9.41%
5일
-5.53%
1개월
-34.71%
3개월
3.11%
6개월
-2.77%
연초 이후
-51.92%
1년
-46.28%
5년
-73.77%
10년
-80.33%
 

소개: GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

직원 수: 1,300

뉴스

긍정적
중립
부정적
투자 심리 3개월
긍정적 5.1%
중립 94.9%
부정적 0%
중립
Business Wire
9일 전
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
중립
Business Wire
14일 전
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
중립
Business Wire
지난달
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
긍정적
Zacks Investment Research
지난달
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
3 Promising Genomics Stocks in the Spotlight in 2026
중립
Business Wire
지난달
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
긍정적
Benzinga
지난달
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
중립
Business Wire
지난달
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
긍정적
Zacks Investment Research
지난달
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
긍정적
Seeking Alpha
지난달
GeneDx: Why I Think The Worst Is Behind The Business
GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.
GeneDx: Why I Think The Worst Is Behind The Business
중립
Business Wire
2개월 전
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx launches a new online offering to expand access to exome testing and help more children and families get answers sooner.
GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
Lightweight Charts™를 사용해 가격 차트를 구현했어요.